| Previous Close | 30 |
| Open | 30.57 |
| Day High | 30.68 |
| Day Low | 28.93 |
| 52-Week High | 37.83 |
| 52-Week Low | 11.39 |
| Volume | 645,977 |
| Average Volume | 455,911 |
| Market Cap | 219.24M |
| PE | -0.74 |
| EPS | -39.55 |
| Moving Average 50 Days | 22.57 |
| Moving Average 200 Days | 24.51 |
| Change | -0.68 |
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Nov 12, 2025 10:01 PM GMT
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe e
Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Sep 04, 2025 8:15 PM GMT
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe
Surrozen to Present at Upcoming Healthcare Investor Conference
GlobeNewswire Inc.
Aug 06, 2025 8:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and reg